Skip to main content

Anchiano to Hold Virtual Annual Meeting of Shareholders

Written by Customer Service on . Posted in Public Companies.

CAMBRIDGE, Mass., April 17, 2020 (GLOBE NEWSWIRE) — Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (the “Company”) today announced it has elected to hold its 2020 Annual General Meeting of Shareholders (the “Annual Meeting”) as a virtual meeting due to the ongoing public health concerns related to the coronavirus (COVID-19) pandemic. The Annual Meeting will still be held on April 23, 2020 at 11:00 a.m. (Eastern Daylight Time).
As described in the proxy materials for the Annual Meeting (the “Proxy Materials”), shareholders as of the close of business on March 23, 2020, the record date, are entitled to participate in the Annual Meeting. Shareholders can participate in the Annual Meeting via the internet by visiting https://anchiano.webex.com/anchiano/j.php?MTID=m99b0b42faed9b725d14a1b66c65252b7 and entering the meeting number (280 326 067). Shareholders can also participate in the Annual Meeting by dialing 1-415-655-0003 in the United States, or 1-809-454-387 in Israel, and entering the identifying information described above. Shareholders will not be able to attend the Annual Meeting in person. We encourage shareholders to log into the website and access the webcast before the Annual Meeting’s start time.All shareholders are encouraged to vote and submit their proxies in advance of the Annual Meeting by one of the methods described in the Proxy Materials. The proxy card previously distributed with the Proxy Materials will not be updated to reflect the change in meeting format and may continue to be used to vote shares in connection with the Annual Meeting. Shareholders who have previously sent in proxies do not need to take any further action.About the Company
The Company is a biopharmaceutical company dedicated to the discovery, development, and commercialization of novel targeted therapies to treat cancer in areas of significant clinical need located in Cambridge, MA.  The Company is developing small-molecule pan-RAS inhibitors and inhibitors of PDE10 and the b-catenin pathway.  For more information on the Company, please visit www.anchiano.com.Forward-Looking Statements
This press release contains “forward-looking statements” that are subject to risks and uncertainties.  These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions, many of which are beyond the control of the Company, including, without limitation, the risk factors and other matters set forth in its filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2019.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.Company Contact:
Frank Haluska, M.D., Ph.D.
President and Chief Executive Officer
info@anchiano.comInvestor Contact:
Ashley R. Robinson
Managing Director
LifeSci Advisors, LLC
617-430-7577
arr@lifesciadvisors.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.